Chen et al. investigated the impact of AZD4547, a FGFR inhibitor, on FGFR2-amplified gastric cancer cell line KatoIII, using a kinome-wide CRISPR knock-out screening panel. This evidence concerns the gene FGFR2 and gastric cancer.